30 April 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched in the US Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the US Food and Drug Administration, the company said.

The Albenza brand and generic had US sales of approximately USD 27m MAT for the most recent twelve months ending in November 2020 according to IQVIA Health.

Dr. Reddy's Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

Albenza is a trademark of Glaxosmithkline (NYSE: GSK).

Dr. Reddy's Laboratories is an integrated pharmaceutical company. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.